HealthMyne Appoints National Oncology Leader to Board of Directors

By HealthMyne | January 18, 2021 | Press Release

Veteran physician executive Mimi Huizinga brings a deep understanding of the role novel data plays in treatment development and delivery

Madison, WISCONSIN, January 19, 2021 - HealthMyne, a pioneer in applied radiomics, announced today the appointment of Mimi Huizinga, MD, MPH, FACP, to its board of directors. Dr. Huizinga is the Vice President and Head of U.S. Oncology Medical, Novartis.  Huizinga is a physician executive with deep experience achieving clinical excellence across the care continuum driven by evidence-based care, data, and analytics.

Previously, Huizinga held the role of Vice President, Strategic Data and Digital, U.S. Oncology, with Novartis. Prior to that, she served as Chief Health Information Officer and Vice President, Chief Clinical Officer, Population Health, with Premier Inc.

“We are delighted to add an oncology physician leader with the transformative digital and data expertise Dr. Huizinga brings to our board,” said Rose Higgins, CEO, HealthMyne. “Mimi’s knowledge, experience and guidance will be instrumental as we continue to develop tools that empower life science companies, clinical researchers and health systems to leverage novel radiomic data.”

“Mimi’s proven success in operationalizing data and digital strategies across therapy development, clinical trials, and personalized treatment delivery provides her a unique perspective to the material impact radiomic data will have on patient’s potential future risk and clinical outcomes”, says T. Rock Mackie, Chairman of the Board, HealthMyne.

“Medical images contain a wealth of untapped information critical to the development and delivery of the best possible treatments, offering the potential for radiomics to transform cancer care,” said Huizinga. “I am proud to join HealthMyne’s board to help advance the application of radiomic insights in the next generation of precision medicine and to contribute to its goal of ensuring the right patient treatment every time.”